54Gene

Overview

54Gene was an African genomics research and services company founded by Abasi Ene-Obong in 2019 and accepted into Y Combinator's Winter 2019 batch. Named for Africa's 54 countries, it sought to correct African underrepresentation in genomic research through hospital partnerships, local sequencing, biobanking, pharmaceutical research, clinical infrastructure, and drug discovery.^[1][2]

The company began winding down in July 2023. The strongest proximate business explanation is a duration mismatch: pandemic diagnostics produced near-term revenue, while the core genomics and pharmaceutical model required sustained capital over much longer timelines. Leadership changes, repeated layoffs, financing pressure, and governance disputes followed, but no audited record proves a single exclusive cause.

The company's most consequential unresolved issue is stewardship. The current physical custodian remains unresolved, and public evidence does not establish storage funding, the legal controller, or final disposition of the full biobank and associated data.

Founding Story

Ene-Obong grew up in Calabar, Nigeria, studied human molecular genetics and cancer biology, and later earned a bioscience-management degree. He told TechCrunch: “I always wanted to do stuff that brought the African continent into the global healthcare debate.”^[2]

The company name encoded a pan-African ambition. Its early model used research partnerships with Nigerian hospitals rather than direct-to-consumer ancestry testing. Research assistants collected blood, tumor tissue, or saliva under active studies across a network that Wired later described as 17 hospitals.^[3]

Ene-Obong said hospital studies received institutional-review-board review and participants gave informed consent. An IFC profile similarly described protocols for collection, consent, and privacy.^[4] However, the underlying consent forms, ethics approvals, material-transfer agreements, and insolvency or sale provisions were not published in the sources reviewed. The claims should therefore be reported as company statements, not independently audited governance.

The early projection was roughly 40,000 samples from current studies, later expanding toward 200,000. These were targets, not verified completed counts. The Nigerian 100K Genome Project title similarly described an ambition. Its first consortium publication concerned program and governance design, not proof that 100,000 whole genomes had already been sequenced.^[5][6]

The business thesis evolved from assembling representative cohorts toward pharmaceutical R&D, sequencing services, diagnostics, clinical trials, and target discovery. Ene-Obong later said: “Our goal is not so much to create the data and have anybody buy it.”^[7] The intended product was research partnership and discovery, not sale of raw samples as the primary business.

Timeline

• Winter 2019: 54Gene entered Y Combinator.
• July 2019: The company announced a $4.5 million seed round and hospital-based collection strategy.
• 2020: A Lagos facility received Illumina sequencing and microarray platforms for local genotyping, sequencing, and analysis.^[8]
• 2020: 54Gene launched COVID-19 diagnostics, creating near-term revenue alongside long-horizon genomics work.
• September 2021: A $25 million Series B brought disclosed funding above $45 million.^[9]
• May 2022: The Nigerian 100K Genome Project announced its first consortium-led publication.^[10]
• August 2022: The company laid off 95 employees, mostly COVID laboratory and sales contractors, as testing demand fell.
• October 2022: Ene-Obong stepped down as CEO; general counsel Teresia Bost became interim CEO.^[11]
• March 2023: Ron Chiarello became CEO; the company announced fundraising and partnership goals, then cut roughly 25 percent of remaining staff.^[12][13]
• July 2023: 54Gene began winding down.
• September 2023: The website was unavailable and Chiarello confirmed financial inability to continue.
• August 2025: Court-document reporting said a Lagos injunction blocked a proposed $3 million asset sale that included biodata associated with 100,000 Nigerians.^[14]